Tubulis raises €344.0M Series C round
30 October 2025· Munich, Germany· health, oncology, biotech, b2b, deep_hardware
The combined capital will enable the company to initiate pivotal trials with lead antibody-drug conjugate (ADC) candidate TUB-040, explore earlier lines of treatment in ovarian cancer, expand into combination regimens and new solid tumor indications, advance the pipeline including clinical-stage candidate TUB-030, and further optimize its proprietary ADC platform technologies.
Investors
LeadVenrock Healthcare Capital Partners
Also participating
High-Tech GründerfondsBayern KapitalEQT Life SciencesAndera PartnersFidelity Management & Research CompanyOCCIDENTSeventure PartnersWellington ManagementFund+Deep Track CapitalFrazier Life SciencesJanus Henderson InvestorsBlackstone Multi-Asset InvestingAscenta CapitalNextech Invest
About Tubulis
Stage
Series C
Headquarters
Munich, Germany
Founded
2019
Team Size
51–200
Sectors
healthoncologybiotechb2bdeep_hardware